Evaluation of carboplatin (NSC 241240) in patients with recurrent or metastatic renal cell carcinoma View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1990-05

AUTHORS

Donald L. Trump, Paul Elson

ABSTRACT

Eighteen evaluable patients with metastatic or recurrent renal cell carcinoma were treated with carboplatin. Fourteen patients received 400 mg/m2 as the initial dose, and four patients received reduced doses based on prior radiation therapy and/or elevated serum creatinine. No responses were seen. Median survival of these 18 patients was 8.3 months. Risk group status which previously has been identified as an important indicator of survival was predictive for survival in this study. Patients in the most favorable risk groups had a median survival of 21.2 months vs. 6.6 months for the most unfavorable risk groups. No lethal toxicities occurred with the administration of carboplatin; however, 66% of patients received doses of sufficient magnitude to cause severe or life threatening thrombocytopenia or anemia. More... »

PAGES

201-203

References to SciGraph publications

  • 1984. Experimental Antitumor Activity of Platinum Coordination Complexes in PLATINUM COORDINATION COMPLEXES IN CANCER CHEMOTHERAPY
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/bf00177260

    DOI

    http://dx.doi.org/10.1007/bf00177260

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1047512127

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/2200758


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Oncology and Carcinogenesis", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Anemia", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antineoplastic Agents", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Carboplatin", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Carcinoma, Renal Cell", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Drug Evaluation", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Female", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Kidney Neoplasms", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Male", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Neoplasm Recurrence, Local", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Organoplatinum Compounds", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Prognosis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Thrombocytopenia", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "UW Carbone Cancer Center", 
              "id": "https://www.grid.ac/institutes/grid.412639.b", 
              "name": [
                "University of Wisconsin Clinical Cancer Center, (CA-21076), Madison, WI, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Trump", 
            "givenName": "Donald L.", 
            "id": "sg:person.0710021450.77", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0710021450.77"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Dana\u2013Farber Cancer Institute", 
              "id": "https://www.grid.ac/institutes/grid.65499.37", 
              "name": [
                "Dana-Farber Cancer Institute, Harvard School of Public Health, (CA-23318), Boston, MA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Elson", 
            "givenName": "Paul", 
            "id": "sg:person.0773221263.82", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0773221263.82"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1007/978-1-4613-2837-7_19", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1029734143", 
              "https://doi.org/10.1007/978-1-4613-2837-7_19"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1097/00000421-198212000-00014", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1045278392"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1097/00000421-198212000-00014", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1045278392"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1002/1097-0142(19860115)57:2<222::aid-cncr2820570206>3.0.co;2-x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1053486340"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://app.dimensions.ai/details/publication/pub.1079529449", 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://app.dimensions.ai/details/publication/pub.1081713873", 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "1990-05", 
        "datePublishedReg": "1990-05-01", 
        "description": "Eighteen evaluable patients with metastatic or recurrent renal cell carcinoma were treated with carboplatin. Fourteen patients received 400 mg/m2 as the initial dose, and four patients received reduced doses based on prior radiation therapy and/or elevated serum creatinine. No responses were seen. Median survival of these 18 patients was 8.3 months. Risk group status which previously has been identified as an important indicator of survival was predictive for survival in this study. Patients in the most favorable risk groups had a median survival of 21.2 months vs. 6.6 months for the most unfavorable risk groups. No lethal toxicities occurred with the administration of carboplatin; however, 66% of patients received doses of sufficient magnitude to cause severe or life threatening thrombocytopenia or anemia.", 
        "genre": "research_article", 
        "id": "sg:pub.10.1007/bf00177260", 
        "inLanguage": [
          "en"
        ], 
        "isAccessibleForFree": false, 
        "isFundedItemOf": [
          {
            "id": "sg:grant.2693289", 
            "type": "MonetaryGrant"
          }, 
          {
            "id": "sg:grant.2693274", 
            "type": "MonetaryGrant"
          }
        ], 
        "isPartOf": [
          {
            "id": "sg:journal.1094201", 
            "issn": [
              "0167-6997", 
              "1573-0646"
            ], 
            "name": "Investigational New Drugs", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "2", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "8"
          }
        ], 
        "name": "Evaluation of carboplatin (NSC 241240) in patients with recurrent or metastatic renal cell carcinoma", 
        "pagination": "201-203", 
        "productId": [
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/bf00177260"
            ]
          }, 
          {
            "name": "readcube_id", 
            "type": "PropertyValue", 
            "value": [
              "e254e71b652b9435a35b670fc2119797dd183144001356df30c0a822d074beab"
            ]
          }, 
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1047512127"
            ]
          }, 
          {
            "name": "nlm_unique_id", 
            "type": "PropertyValue", 
            "value": [
              "8309330"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "2200758"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/bf00177260", 
          "https://app.dimensions.ai/details/publication/pub.1047512127"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2019-04-15T08:53", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000374_0000000374/records_119750_00000001.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "http://link.springer.com/10.1007/BF00177260"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf00177260'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf00177260'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf00177260'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf00177260'


     

    This table displays all metadata directly associated to this object as RDF triples.

    149 TRIPLES      21 PREDICATES      47 URIs      34 LITERALS      22 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/bf00177260 schema:about N3c12be8b03194d348ccf124db50d778f
    2 N44444bbc3b6b43cfb202c879e525874c
    3 Na3de8073a9ab4ada88cf59cdbb6baa8e
    4 Na71ce10b510f4b7aa2d9d3400038f5cb
    5 Na96a06b8a4bd45d1aaf561a85b40b66d
    6 Nacb6b181bd914c968d5472352b6a0b38
    7 Nc3da06a5ecbb4ded951044188c70e9d4
    8 Nc96704a06c6a41f689fa076d7e44d79d
    9 Nc9c306a021ce4f7e81b445643614f0d6
    10 Nd03d1d4e64024d4f8b5f3bb179448ba9
    11 Ndd20af8fac6241b6a947fc8d4011a394
    12 Ne0c7a64ee5984746a0d12560f83450ed
    13 Nedbf9580dadc439a93819f71a8ecff04
    14 anzsrc-for:11
    15 anzsrc-for:1112
    16 schema:author N6a93d3b4390648b3a1d8fd4965473b5d
    17 schema:citation sg:pub.10.1007/978-1-4613-2837-7_19
    18 https://app.dimensions.ai/details/publication/pub.1079529449
    19 https://app.dimensions.ai/details/publication/pub.1081713873
    20 https://doi.org/10.1002/1097-0142(19860115)57:2<222::aid-cncr2820570206>3.0.co;2-x
    21 https://doi.org/10.1097/00000421-198212000-00014
    22 schema:datePublished 1990-05
    23 schema:datePublishedReg 1990-05-01
    24 schema:description Eighteen evaluable patients with metastatic or recurrent renal cell carcinoma were treated with carboplatin. Fourteen patients received 400 mg/m2 as the initial dose, and four patients received reduced doses based on prior radiation therapy and/or elevated serum creatinine. No responses were seen. Median survival of these 18 patients was 8.3 months. Risk group status which previously has been identified as an important indicator of survival was predictive for survival in this study. Patients in the most favorable risk groups had a median survival of 21.2 months vs. 6.6 months for the most unfavorable risk groups. No lethal toxicities occurred with the administration of carboplatin; however, 66% of patients received doses of sufficient magnitude to cause severe or life threatening thrombocytopenia or anemia.
    25 schema:genre research_article
    26 schema:inLanguage en
    27 schema:isAccessibleForFree false
    28 schema:isPartOf N34ebb5fa97f345f5bca2186ac3220a07
    29 N9bf735a35e1747ac9791e72508d6d651
    30 sg:journal.1094201
    31 schema:name Evaluation of carboplatin (NSC 241240) in patients with recurrent or metastatic renal cell carcinoma
    32 schema:pagination 201-203
    33 schema:productId N2a413ae834ee4fb9874d714a66831e96
    34 N411bbae012ee41ca9fc745afc951d20d
    35 N4692d582d4b5477581348ab4c57ed69c
    36 N8b1d5a1c2261446b8ca9fbfc34fb88ac
    37 Ne435822f523f446fbca8d9f444b76ce8
    38 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047512127
    39 https://doi.org/10.1007/bf00177260
    40 schema:sdDatePublished 2019-04-15T08:53
    41 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    42 schema:sdPublisher N4f4951b621ce4738bcdf785c99529683
    43 schema:url http://link.springer.com/10.1007/BF00177260
    44 sgo:license sg:explorer/license/
    45 sgo:sdDataset articles
    46 rdf:type schema:ScholarlyArticle
    47 N0259f55be08a4ab5b65ec08b86451d96 rdf:first sg:person.0773221263.82
    48 rdf:rest rdf:nil
    49 N2a413ae834ee4fb9874d714a66831e96 schema:name pubmed_id
    50 schema:value 2200758
    51 rdf:type schema:PropertyValue
    52 N34ebb5fa97f345f5bca2186ac3220a07 schema:issueNumber 2
    53 rdf:type schema:PublicationIssue
    54 N3c12be8b03194d348ccf124db50d778f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    55 schema:name Carboplatin
    56 rdf:type schema:DefinedTerm
    57 N411bbae012ee41ca9fc745afc951d20d schema:name doi
    58 schema:value 10.1007/bf00177260
    59 rdf:type schema:PropertyValue
    60 N44444bbc3b6b43cfb202c879e525874c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    61 schema:name Female
    62 rdf:type schema:DefinedTerm
    63 N4692d582d4b5477581348ab4c57ed69c schema:name dimensions_id
    64 schema:value pub.1047512127
    65 rdf:type schema:PropertyValue
    66 N4f4951b621ce4738bcdf785c99529683 schema:name Springer Nature - SN SciGraph project
    67 rdf:type schema:Organization
    68 N6a93d3b4390648b3a1d8fd4965473b5d rdf:first sg:person.0710021450.77
    69 rdf:rest N0259f55be08a4ab5b65ec08b86451d96
    70 N8b1d5a1c2261446b8ca9fbfc34fb88ac schema:name nlm_unique_id
    71 schema:value 8309330
    72 rdf:type schema:PropertyValue
    73 N9bf735a35e1747ac9791e72508d6d651 schema:volumeNumber 8
    74 rdf:type schema:PublicationVolume
    75 Na3de8073a9ab4ada88cf59cdbb6baa8e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    76 schema:name Anemia
    77 rdf:type schema:DefinedTerm
    78 Na71ce10b510f4b7aa2d9d3400038f5cb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    79 schema:name Humans
    80 rdf:type schema:DefinedTerm
    81 Na96a06b8a4bd45d1aaf561a85b40b66d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    82 schema:name Carcinoma, Renal Cell
    83 rdf:type schema:DefinedTerm
    84 Nacb6b181bd914c968d5472352b6a0b38 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    85 schema:name Neoplasm Recurrence, Local
    86 rdf:type schema:DefinedTerm
    87 Nc3da06a5ecbb4ded951044188c70e9d4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    88 schema:name Kidney Neoplasms
    89 rdf:type schema:DefinedTerm
    90 Nc96704a06c6a41f689fa076d7e44d79d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    91 schema:name Male
    92 rdf:type schema:DefinedTerm
    93 Nc9c306a021ce4f7e81b445643614f0d6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    94 schema:name Thrombocytopenia
    95 rdf:type schema:DefinedTerm
    96 Nd03d1d4e64024d4f8b5f3bb179448ba9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    97 schema:name Prognosis
    98 rdf:type schema:DefinedTerm
    99 Ndd20af8fac6241b6a947fc8d4011a394 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    100 schema:name Antineoplastic Agents
    101 rdf:type schema:DefinedTerm
    102 Ne0c7a64ee5984746a0d12560f83450ed schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    103 schema:name Drug Evaluation
    104 rdf:type schema:DefinedTerm
    105 Ne435822f523f446fbca8d9f444b76ce8 schema:name readcube_id
    106 schema:value e254e71b652b9435a35b670fc2119797dd183144001356df30c0a822d074beab
    107 rdf:type schema:PropertyValue
    108 Nedbf9580dadc439a93819f71a8ecff04 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    109 schema:name Organoplatinum Compounds
    110 rdf:type schema:DefinedTerm
    111 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    112 schema:name Medical and Health Sciences
    113 rdf:type schema:DefinedTerm
    114 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
    115 schema:name Oncology and Carcinogenesis
    116 rdf:type schema:DefinedTerm
    117 sg:grant.2693274 http://pending.schema.org/fundedItem sg:pub.10.1007/bf00177260
    118 rdf:type schema:MonetaryGrant
    119 sg:grant.2693289 http://pending.schema.org/fundedItem sg:pub.10.1007/bf00177260
    120 rdf:type schema:MonetaryGrant
    121 sg:journal.1094201 schema:issn 0167-6997
    122 1573-0646
    123 schema:name Investigational New Drugs
    124 rdf:type schema:Periodical
    125 sg:person.0710021450.77 schema:affiliation https://www.grid.ac/institutes/grid.412639.b
    126 schema:familyName Trump
    127 schema:givenName Donald L.
    128 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0710021450.77
    129 rdf:type schema:Person
    130 sg:person.0773221263.82 schema:affiliation https://www.grid.ac/institutes/grid.65499.37
    131 schema:familyName Elson
    132 schema:givenName Paul
    133 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0773221263.82
    134 rdf:type schema:Person
    135 sg:pub.10.1007/978-1-4613-2837-7_19 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029734143
    136 https://doi.org/10.1007/978-1-4613-2837-7_19
    137 rdf:type schema:CreativeWork
    138 https://app.dimensions.ai/details/publication/pub.1079529449 schema:CreativeWork
    139 https://app.dimensions.ai/details/publication/pub.1081713873 schema:CreativeWork
    140 https://doi.org/10.1002/1097-0142(19860115)57:2<222::aid-cncr2820570206>3.0.co;2-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1053486340
    141 rdf:type schema:CreativeWork
    142 https://doi.org/10.1097/00000421-198212000-00014 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045278392
    143 rdf:type schema:CreativeWork
    144 https://www.grid.ac/institutes/grid.412639.b schema:alternateName UW Carbone Cancer Center
    145 schema:name University of Wisconsin Clinical Cancer Center, (CA-21076), Madison, WI, USA
    146 rdf:type schema:Organization
    147 https://www.grid.ac/institutes/grid.65499.37 schema:alternateName Dana–Farber Cancer Institute
    148 schema:name Dana-Farber Cancer Institute, Harvard School of Public Health, (CA-23318), Boston, MA, USA
    149 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...